Iterum Therapeutics Plc (ITRM)

$0.03 -0.04 (-57.39%)
Market Cap 1.60M
Revenue (ttm) 0.00
Net Income (ttm) -24.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -2.88
Volume 65,735,500
Avg Vol 19,797,338
Day's Range N/A - N/A
Shares Out 53.29M
Stochastic %K 2%
Beta 2.96
Analysts Hold
Price Target $9.00

Company Profile

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel...

Industry: Biotechnology
Sector: Healthcare
Phone: 353 1 903 8354
Address:
3 Dublin Landings, North Wall Quay, Dublin, Ireland
kingstock84
kingstock84 May. 27 at 10:38 AM
$ITRM i wish i wake up tomorrow and this stock would be at $4 per share
1 · Reply
Amb8675309
Amb8675309 May. 27 at 1:40 AM
$ITRM shionogi has completed 4 transactions within 6 months, totaling $4.7Billion USD. That’s an extraordinary pace of capital deployment, given Shionogi’s size. Can they squeeze one more purchase, of Orlynvah? If so, what’s their timeline? Looks like June or July… or they hold off??? It’s definitely a nail biter….
1 · Reply
Amb8675309
Amb8675309 May. 27 at 1:35 AM
$ITRM well yellowjacker’s May 27 timeline has come and gone and we’ve got no announcement. I did see that Michael Dunne, former board member, made an inside purchase right before liquidation filing of 6000 shares, so he’s buying😂and he threw down $2191 .😂
1 · Reply
Biorocksme
Biorocksme May. 27 at 12:54 AM
$ITRM The company is dissolved and drug/ patents are at the mercy of a court liquidation process Would doctors still rx to patients knowing there is no legal recourse if a pill was bad? 🤡
0 · Reply
Pharmstock1
Pharmstock1 May. 27 at 12:13 AM
$ITRM long term lurker and holder since pre FDA approval days. I work in retail pharmacy and was on the phone with McKesson today for something unrelated but was able to ask about orlynvah. They told me it is only available through McKesson plasma and biologics but the rep also said everything on their side was red indicating that it was not available to order by anyone at this time. Can’t speak for alto but sounds like McKesson isn’t currently distributing.
2 · Reply
StonkZombie
StonkZombie May. 26 at 10:09 PM
$ITRM AMB spamming the hell out of this board today. Wow, 8 posts in 12 hours. Must be desperate as hell to get new blood in this. Hey, if a company that sells uUTI antibiotics is potentially worth a billion dollars, as she asserts, then why isn't $SPRO trading at $8-9/share? That's a solid business with GlaxoSmithKline owning nearly 8% of the company and a slew of other big names like Vanguard owning similarly large positions. Exactly the type of institutional ownership that everyone wanted for Iterum. But they have it. A successful company - and they aren't pushing a billon dollars. So why would @ITRMF, this little rinky dink piece of shit delisted company be worth that much? Big pharma can't even get those numbers, lol If the market for uterine tract infection antibiotics is so damn hot? THINK ABOUT IT!! This is 7 cents a share because the company is dead, the drug is competing with the big boys now, and it's always been a small niche to fill. This, her babbling... is nonsense
4 · Reply
Digger22
Digger22 May. 26 at 9:46 PM
$ITRM If I could get paid $1 for every time I refresh this page looking for good news about a buyout, I could easily pay everyone here the $12 a share we are all wishing for🧐.
1 · Reply
CapitalismUSA
CapitalismUSA May. 26 at 9:25 PM
$ITRM FishFucks arrogance most likely pissed off many BPs who were interested in acquiring the company. Now that he is out of the picture they hopefully have renewed interest. Moving him aside is worth $100M in itself.
0 · Reply
Amb8675309
Amb8675309 May. 26 at 8:14 PM
$ITRM the reason to revisit the bear case every day, which is something I do given the size of the position we hold is to make sure that there is a new information that changes the thesis the timeline stuff I know some people find irritating, but the older you get, maybe the better you’ll get at waiting I think some of the people on here are super young and they’re used to quick trades. This is the buyout. I said this at the beginning when I got in I’m here for the buyout and we have to let the process work itself out. There’s nothing we can do. All I can do is keep assessing. Why would someone want this drug? Why would someone not want it and I really can’t come up with a reason not to buy or even if it’s in liquidation. So then you ask, what’s a fair price given that it’s a distressed asset? If you look at the potential revenue from this, it’s gonna be 1-4Bil but then you discount that by 60 to 80% because it’s distressed and that’s how yellow can come up with 750 mil buy out
3 · Reply
Amb8675309
Amb8675309 May. 26 at 7:58 PM
$ITRM CF filed for wind up on 3/27 as dollar a day has nicely outlined. Why did he do that? Could it be, as dollar suggests( and I agree) that he didn’t want to have to share Q4/25 or even Q1 data? That’s why I spent so much time, along with other people, calling Alto Pharmacy. I never identified myself as a shareholder, just as a potential patient and asked multiple pharmacists-they said the drug was getting prescribed by clinics that had a high volume of resistant cases. The key is did those doctors put these patients that keep having infections through step therapy yet again or did they just go straight to Orly? my guess is they used ORLY at the first sign of the next infection/ ie first office visit. Like I said before, my Aetna PPO doesn’t even require prior auth nor medical exception- they leave it to the discretion of the doctor. anyone who buys Orly will want to get prior auth removed➡️Huge script volume➡️huge revenue
1 · Reply
Latest News on ITRM
No data available.
kingstock84
kingstock84 May. 27 at 10:38 AM
$ITRM i wish i wake up tomorrow and this stock would be at $4 per share
1 · Reply
Amb8675309
Amb8675309 May. 27 at 1:40 AM
$ITRM shionogi has completed 4 transactions within 6 months, totaling $4.7Billion USD. That’s an extraordinary pace of capital deployment, given Shionogi’s size. Can they squeeze one more purchase, of Orlynvah? If so, what’s their timeline? Looks like June or July… or they hold off??? It’s definitely a nail biter….
1 · Reply
Amb8675309
Amb8675309 May. 27 at 1:35 AM
$ITRM well yellowjacker’s May 27 timeline has come and gone and we’ve got no announcement. I did see that Michael Dunne, former board member, made an inside purchase right before liquidation filing of 6000 shares, so he’s buying😂and he threw down $2191 .😂
1 · Reply
Biorocksme
Biorocksme May. 27 at 12:54 AM
$ITRM The company is dissolved and drug/ patents are at the mercy of a court liquidation process Would doctors still rx to patients knowing there is no legal recourse if a pill was bad? 🤡
0 · Reply
Pharmstock1
Pharmstock1 May. 27 at 12:13 AM
$ITRM long term lurker and holder since pre FDA approval days. I work in retail pharmacy and was on the phone with McKesson today for something unrelated but was able to ask about orlynvah. They told me it is only available through McKesson plasma and biologics but the rep also said everything on their side was red indicating that it was not available to order by anyone at this time. Can’t speak for alto but sounds like McKesson isn’t currently distributing.
2 · Reply
StonkZombie
StonkZombie May. 26 at 10:09 PM
$ITRM AMB spamming the hell out of this board today. Wow, 8 posts in 12 hours. Must be desperate as hell to get new blood in this. Hey, if a company that sells uUTI antibiotics is potentially worth a billion dollars, as she asserts, then why isn't $SPRO trading at $8-9/share? That's a solid business with GlaxoSmithKline owning nearly 8% of the company and a slew of other big names like Vanguard owning similarly large positions. Exactly the type of institutional ownership that everyone wanted for Iterum. But they have it. A successful company - and they aren't pushing a billon dollars. So why would @ITRMF, this little rinky dink piece of shit delisted company be worth that much? Big pharma can't even get those numbers, lol If the market for uterine tract infection antibiotics is so damn hot? THINK ABOUT IT!! This is 7 cents a share because the company is dead, the drug is competing with the big boys now, and it's always been a small niche to fill. This, her babbling... is nonsense
4 · Reply
Digger22
Digger22 May. 26 at 9:46 PM
$ITRM If I could get paid $1 for every time I refresh this page looking for good news about a buyout, I could easily pay everyone here the $12 a share we are all wishing for🧐.
1 · Reply
CapitalismUSA
CapitalismUSA May. 26 at 9:25 PM
$ITRM FishFucks arrogance most likely pissed off many BPs who were interested in acquiring the company. Now that he is out of the picture they hopefully have renewed interest. Moving him aside is worth $100M in itself.
0 · Reply
Amb8675309
Amb8675309 May. 26 at 8:14 PM
$ITRM the reason to revisit the bear case every day, which is something I do given the size of the position we hold is to make sure that there is a new information that changes the thesis the timeline stuff I know some people find irritating, but the older you get, maybe the better you’ll get at waiting I think some of the people on here are super young and they’re used to quick trades. This is the buyout. I said this at the beginning when I got in I’m here for the buyout and we have to let the process work itself out. There’s nothing we can do. All I can do is keep assessing. Why would someone want this drug? Why would someone not want it and I really can’t come up with a reason not to buy or even if it’s in liquidation. So then you ask, what’s a fair price given that it’s a distressed asset? If you look at the potential revenue from this, it’s gonna be 1-4Bil but then you discount that by 60 to 80% because it’s distressed and that’s how yellow can come up with 750 mil buy out
3 · Reply
Amb8675309
Amb8675309 May. 26 at 7:58 PM
$ITRM CF filed for wind up on 3/27 as dollar a day has nicely outlined. Why did he do that? Could it be, as dollar suggests( and I agree) that he didn’t want to have to share Q4/25 or even Q1 data? That’s why I spent so much time, along with other people, calling Alto Pharmacy. I never identified myself as a shareholder, just as a potential patient and asked multiple pharmacists-they said the drug was getting prescribed by clinics that had a high volume of resistant cases. The key is did those doctors put these patients that keep having infections through step therapy yet again or did they just go straight to Orly? my guess is they used ORLY at the first sign of the next infection/ ie first office visit. Like I said before, my Aetna PPO doesn’t even require prior auth nor medical exception- they leave it to the discretion of the doctor. anyone who buys Orly will want to get prior auth removed➡️Huge script volume➡️huge revenue
1 · Reply
Amb8675309
Amb8675309 May. 26 at 7:51 PM
$ITRM here’s a simple math: $7.2 billion spent to treat uUTIs in 2024. This treatment is dominated by $4-$20/dose drugs and only .2% of uUTIs end up in the hospital, so where’s all the money going? It’s for all these women that get repeat infections and they don’t respond to that first generic and then they end up in what’s called a treatment cascade failure of multiple office visits, lab cultures, a whole bunch of tests, different generics, and the money starts to add up. We ran the number several times and it’s over $2 billion per year You can save if you use ORLY at the first office visit for the women that are highly likely to not respond to the first generic prescribed. This is the same environment that GSK, who spent 600 million to develop bluejepa, will be in, although I like to look at bluejepa as more of a complementary versus direct competitor for a bunch of reasons I won’t discuss here. Any new drug in this space has to steal market share from $4GENERICS from 1953.
0 · Reply
Amb8675309
Amb8675309 May. 26 at 7:39 PM
$ITRM all the other things that have happened with antibiotics in the first part of this year is all the icing the main business case that Fishman pitched with a limited sales team and it’s the same business case now for a buyer that buys Orly is to cut down on the amount of expense for all the women that aren’t better with the first generic antibiotics they get at their first office visit. There are whole host of expenses that come out of these repeat infection cases 35% of those people that don’t respond well are women covered under Medicare i.e. post menopausal women and they just keep getting one infection after another. It’s a huge amount of expense and the major insurers plus Medicare have to cover these people. I know someone that has a mother that just got her six UTI in one year.
0 · Reply
GatorMcKlusky
GatorMcKlusky May. 26 at 7:38 PM
$ITRM Volume picked up in the last hour big time. Seems to be a trend here. Anyway, the more the merrier. Join us on our rocky road to glory...
0 · Reply
Amb8675309
Amb8675309 May. 26 at 7:30 PM
$ITRM if you look at the $7.2 billion that was spent in 2024 to treat U.S. uUTI infections, only .2% of those women ended up at the hospital. very few uUTIs turned into cUTIs requiring hospital admission. Where the money savings is going to be on the uncomplicated side is for the women that don’t respond after the first generic that is empirically prescribed. I’m talking about 26 million infections where patient could end up having to take multiple generics multiple office visits there’s a whole treatment cascade failure is what they call it, that generates over $2 billion a year. that is the TAM this drug is going after in the uUTI market. This is the business case/the meat on the bone/the cake. anybody that brings a new drug for resistant uUTIs will target the insurer cost savings you see if you can use Orly as the first drug prescribed. one office visit + one dose of Orly. Save billions. That’s the business case.
1 · Reply
Amb8675309
Amb8675309 May. 26 at 7:22 PM
$ITRM the reason Corey Fishman got super low offers was first of all, big Pharma typically only makes offers on antibiotics once they’ve been commercializing for at least 4 to 5Qs- they need to see revenue risk removed. Of course Fishman had not done the launch at that time so there was no way they were going to be able to come to agreement on a number. anyone that enters into this treatment category with a novel drug is up against a very well entrenched tendency of doctors to reach for generics, some of which have been available since 1953 it’s a genericized low cost treatment environment.
0 · Reply
dadcashflow
dadcashflow May. 26 at 4:39 PM
$ITRM - I filed a request with the High Courts to get an electronic copy of the Statement of Affairs order that was on May 5th. We'll see if they get back to me on if it's available or not.
1 · Reply
DollerADay
DollerADay May. 26 at 4:00 PM
$ITRM What the public may still be missing is that large pharma companies like Shionogi likely are not analyzing Orly through the lens of current scripts or liquidation optics at all. Internally, the conversation may revolve around something far bigger: whether the world is entering a permanent AMR repricing cycle where oral carbapenems become critical healthcare infrastructure assets capable of preventing resistant infections from ever reaching the hospital. In that framework, formulary evolution, hospitalization avoidance, stewardship alignment, government preparedness, and control of the outpatient resistant-UTI pathway may matter far more than near-term revenue. What appears publicly as a distressed biotech asset could privately be modeled as a future category-defining platform whose true value only emerges once physician behavior, payer economics, and global AMR policy fully converge.
1 · Reply
DollerADay
DollerADay May. 26 at 3:57 PM
$ITRM If Shionogi believes Orlynvah can evolve from a niche resistant-uUTI therapy into trusted first-line outpatient intervention, the strategic implications become enormous. The drug is no longer simply an antibiotic — it becomes a hospital-displacement platform capable of intercepting resistant infections before escalation into cUTIs, IV therapy, or inpatient admission. Combined with accelerating AMR policy momentum and improving formulary access, Orlynvah could become the foundation of a new oral carbapenem treatment paradigm. Blockbuster status. A Shionogi-backed Orlynvah would benefit from global AMR credibility, government relationships, payer leverage, infectious disease infrastructure, and the ability to shape physician behavior at scale. If the company succeeds in positioning the drug as the preferred early intervention for resistant outpatient infections, it could redefine the oral UTI market before competitors fully mature — transforming into a anti-infective franchise.
0 · Reply
mallanaga
mallanaga May. 26 at 2:21 PM
$ITRM So I asked @Dollaraday to cool it with the dates (for which he blocked me…) after saying yet again that _this_ was the day to keep an eye on. It’s just annoying, and giving folks another reason to refresh this cursed website 50 times a day. Don’t get me wrong, I like the stock, but the amount of misinformation flowing out of folks (or blatant lies for that matter) is infuriating.
2 · Reply
BrianKuo0925
BrianKuo0925 May. 26 at 2:05 PM
$ITRM It seems somebody is buying the shares. Good sign!!
1 · Reply
YakoCapital
YakoCapital May. 26 at 8:30 AM
$ITRM For your reading pleasure. https://www.algoodbody.com/insights-publications/alg-recent-work
4 · Reply
Amb8675309
Amb8675309 May. 26 at 8:25 AM
$ITRM
0 · Reply